According to Latest Study, the global market for Peptide CDMO Pharmaceutical should grow from US$ million in 2023 to US$ million by 2030, with a CAGR of % for the period of 2024-2030.

By country, China accounted for percent of the global market last year and China’s market share increased from percent to percent. China Peptide CDMO Pharmaceutical market should grow from US$ million in 2023 to US$ million by 2030, with a CAGR of % for the period of 2024-2030. The United States Peptide CDMO Pharmaceutical market should grow from US$ million in 2023 to US$ million by 2030, with a CAGR of % for the period of 2024-2030.

By segment, Peptide Supplements grew percent to account for percent of the total market sales, and Peptide Vaccines grew percent.

This report studies and analyses global Peptide CDMO Pharmaceutical status and future trends, to help determine the Peptide CDMO Pharmaceutical market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for Peptide CDMO Pharmaceutical, and provides market size (US$ million) and Year-over-Year growth, considering 2022 as the base year.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

To assess the competitive environment within the market including supplier revenue, market share, and company profiles.

Highlights

(1) Global Peptide CDMO Pharmaceutical market size, history data 2018-2023, and forecast data 2024-2029, (US$ million)

(2) Global Peptide CDMO Pharmaceutical by company, revenue, market share and industry ranking 2018-2023, (US$ million)

(3) China Peptide CDMO Pharmaceutical by company, revenue, market share and industry ranking 2018-2023, (US$ million)

(4) Global Peptide CDMO Pharmaceutical key consuming regions, consumption value and demand structure

(5) Peptide CDMO Pharmaceutical industry chains, upstream, midstream and downstream

Market segment by players, this report covers

Ambiopharm

Auspep

Bachem

Bcn Peptide

Cpc Scientific

Creative Peptides

Chinese Peptide

Csbio

Corden Pharma

Polypeptide

Hybio Pharmaceutical

Peptide Institute

Pepscan

Almac

Vivitide

Creosalus Inc

Scinopharm

Senn Chemicals

Belyntic

Ferring Pharma

Numaferm

Hybio Pharmaceutical

Provepharm Life Solutions

Enzene Biosciences

Piramal Pharma

Market segment by Type, covers

Liquid-phase Peptide Synthesis（LPPS）

Solid-phase Peptide Synthesis（SPPS）

Mixed Phase

Market segment by Application, can be divided into

Peptide Supplements

Peptide Vaccines

Others

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa

Report Includes:

Chapter 1: to describe Peptide CDMO Pharmaceutical product scope, global consumption value, China consumption value, development opportunities, challenges, trends, and policies.

Chapter 2: Global Peptide CDMO Pharmaceutical market share and ranking of major manufacturers, revenue, 2018-2023

Chapter 3: China Peptide CDMO Pharmaceutical market share and ranking of major manufacturers, revenue, 2018-2023

Chapter 4: Peptide CDMO Pharmaceutical industry chain, upstream, medium-stream, and downstream.

Chapter 5: Segment by Type, consumption value, percent & CAGR, 2018-2029

Chapter 6: Segment by Application, consumption value, percent & CAGR, 2018-2029

Chapter 7: Segment in regional level, consumption value, percent & CAGR, 2018-2029

Chapter 8: Segment in country level, consumption value, percent & CAGR, 2018-2029

Chapter 9: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, revenue, gross margin.

Chapter 10: Conclusions

1 Market Overview

1.1 Peptide CDMO Pharmaceutical Definition

1.2 Global Peptide CDMO Pharmaceutical Market Size and Forecast

1.3 China Peptide CDMO Pharmaceutical Market Size and Forecast

1.4 China Percentage in Global Market

1.5 Peptide CDMO Pharmaceutical Market Size: China VS Global Growth Rate, 2019-2030

1.6 Peptide CDMO Pharmaceutical Market Dynamics

1.6.1 Peptide CDMO Pharmaceutical Market Drivers

1.6.2 Peptide CDMO Pharmaceutical Market Restraints

1.6.3 Peptide CDMO Pharmaceutical Industry Trends

1.6.4 Peptide CDMO Pharmaceutical Industry Policy

2 Global Leading Players and Market Share

2.1 By Revenue of Peptide CDMO Pharmaceutical, Global Market Share by Company, 2019-2024

2.2 Global Peptide CDMO Pharmaceutical Participants, Market Position (Tier 1, Tier 2, and Tier 3)

2.3 Global Peptide CDMO Pharmaceutical Concentration Ratio

2.4 Global Peptide CDMO Pharmaceutical Mergers & Acquisitions, Expansion Plans

2.5 Global Peptide CDMO Pharmaceutical Major Companies Product Type

2.6 Head Office and Peptide CDMO Pharmaceutical Production Site of Key Manufacturer

3 China Leading Players, Market Share and Ranking

3.1 By Revenue of Peptide CDMO Pharmaceutical, China Market Share by Company, 2019-2024

3.2 China Peptide CDMO Pharmaceutical Participants, Market Position (Tier 1, Tier 2, and Tier 3)

4 Industry Chain Analysis

4.1 Peptide CDMO Pharmaceutical Industry Chain

4.2 Peptide CDMO Pharmaceutical Upstream Analysis

4.2.1 Peptide CDMO Pharmaceutical Core Raw Materials

4.2.2 Main Manufacturers of Peptide CDMO Pharmaceutical Core Raw Materials

4.3 Midstream Analysis

4.4 Downstream Analysis

4.5 Peptide CDMO Pharmaceutical Production Mode

4.6 Peptide CDMO Pharmaceutical Procurement Model

4.7 Peptide CDMO Pharmaceutical Industry Sales Model and Sales Channels

4.7.1 Peptide CDMO Pharmaceutical Sales Model

4.7.2 Peptide CDMO Pharmaceutical Typical Distributors

5 Sights by Type

5.1 Peptide CDMO Pharmaceutical Classification

5.1.1 Liquid-phase Peptide Synthesis（LPPS）

5.1.2 Solid-phase Peptide Synthesis（SPPS）

5.1.3 Mixed Phase

5.2 By Type, Global Peptide CDMO Pharmaceutical Consumption Value & CAGR, 2019 VS 2024 VS 2030

5.3 By Type, Global Peptide CDMO Pharmaceutical Consumption Value, 2019-2030

6 Sights by Application

6.1 Peptide CDMO Pharmaceutical Segment by Application

6.1.1 Peptide Supplements

6.1.2 Peptide Vaccines

6.1.3 Others

6.2 By Application, Global Peptide CDMO Pharmaceutical Consumption Value & CAGR, 2019 VS 2024 VS 2030

6.3 By Application, Global Peptide CDMO Pharmaceutical Consumption Value, 2019-2030

7 Sales Sights by Region

7.1 By Region, Global Peptide CDMO Pharmaceutical Consumption Value, 2019 VS 2024 VS 2030

7.2 By Region, Global Peptide CDMO Pharmaceutical Consumption Value, 2019-2030

7.3 North America

7.3.1 North America Peptide CDMO Pharmaceutical & Forecasts, 2019-2030

7.3.2 By Country, North America Peptide CDMO Pharmaceutical Market Size Market Share

7.4 Europe

7.4.1 Europe Peptide CDMO Pharmaceutical Market Size & Forecasts, 2019-2030

7.4.2 By Country, Europe Peptide CDMO Pharmaceutical Market Size Market Share

7.5 Asia Pacific

7.5.1 Asia Pacific Peptide CDMO Pharmaceutical Market Size & Forecasts, 2019-2030

7.5.2 By Country/Region, Asia Pacific Peptide CDMO Pharmaceutical Market Size Market Share

7.6 South America

7.6.1 South America Peptide CDMO Pharmaceutical Market Size & Forecasts, 2019-2030

7.6.2 By Country, South America Peptide CDMO Pharmaceutical Market Size Market Share

7.7 Middle East & Africa

8 Sales Sights by Country Level

8.1 By Country, Global Peptide CDMO Pharmaceutical Market Size & CAGR, 2019 VS 2024 VS 2030

8.2 By Country, Global Peptide CDMO Pharmaceutical Consumption Value, 2019-2030

8.3 U.S.

8.3.1 U.S. Peptide CDMO Pharmaceutical Market Size, 2019-2030

8.3.2 By Type, U.S. Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

8.3.3 By Application, U.S. Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

8.4 Europe

8.4.1 Europe Peptide CDMO Pharmaceutical Market Size, 2019-2030

8.4.2 By Type, Europe Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

8.4.3 By Application, Europe Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

8.5 China

8.5.1 China Peptide CDMO Pharmaceutical Market Size, 2019-2030

8.5.2 By Type, China Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

8.5.3 By Application, China Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

8.6 Japan

8.6.1 Japan Peptide CDMO Pharmaceutical Market Size, 2019-2030

8.6.2 By Type, Japan Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

8.6.3 By Application, Japan Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

8.7 South Korea

8.7.1 South Korea Peptide CDMO Pharmaceutical Market Size, 2019-2030

8.7.2 By Type, South Korea Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

8.7.3 By Application, South Korea Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

8.8 Southeast Asia

8.8.1 Southeast Asia Peptide CDMO Pharmaceutical Market Size, 2019-2030

8.8.2 By Type, Southeast Asia Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

8.8.3 By Application, Southeast Asia Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

8.9 India

8.9.1 India Peptide CDMO Pharmaceutical Market Size, 2019-2030

8.9.2 By Type, India Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

8.9.3 By Application, India Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

8.10 Middle East & Africa

8.10.1 Middle East & Africa Peptide CDMO Pharmaceutical Market Size, 2019-2030

8.10.2 By Type, Middle East & Africa Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

8.10.3 By Application, Middle East & Africa Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

9 Company Profile

9.1 Ambiopharm

9.1.1 Ambiopharm Company Information, Head Office, Market Area and Industry Position

9.1.2 Ambiopharm Company Profile and Main Business

9.1.3 Ambiopharm Peptide CDMO Pharmaceutical Models, Specifications and Application

9.1.4 Ambiopharm Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.1.5 Ambiopharm Recent Developments

9.2 Auspep

9.2.1 Auspep Company Information, Head Office, Market Area and Industry Position

9.2.2 Auspep Company Profile and Main Business

9.2.3 Auspep Peptide CDMO Pharmaceutical Models, Specifications and Application

9.2.4 Auspep Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.2.5 Auspep Recent Developments

9.3 Bachem

9.3.1 Bachem Company Information, Head Office, Market Area and Industry Position

9.3.2 Bachem Company Profile and Main Business

9.3.3 Bachem Peptide CDMO Pharmaceutical Models, Specifications and Application

9.3.4 Bachem Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.3.5 Bachem Recent Developments

9.4 Bcn Peptide

9.4.1 Bcn Peptide Company Information, Head Office, Market Area and Industry Position

9.4.2 Bcn Peptide Company Profile and Main Business

9.4.3 Bcn Peptide Peptide CDMO Pharmaceutical Models, Specifications and Application

9.4.4 Bcn Peptide Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.4.5 Bcn Peptide Recent Developments

9.5 Cpc Scientific

9.5.1 Cpc Scientific Company Information, Head Office, Market Area and Industry Position

9.5.2 Cpc Scientific Company Profile and Main Business

9.5.3 Cpc Scientific Peptide CDMO Pharmaceutical Models, Specifications and Application

9.5.4 Cpc Scientific Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.5.5 Cpc Scientific Recent Developments

9.6 Creative Peptides

9.6.1 Creative Peptides Company Information, Head Office, Market Area and Industry Position

9.6.2 Creative Peptides Company Profile and Main Business

9.6.3 Creative Peptides Peptide CDMO Pharmaceutical Models, Specifications and Application

9.6.4 Creative Peptides Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.6.5 Creative Peptides Recent Developments

9.7 Chinese Peptide

9.7.1 Chinese Peptide Company Information, Head Office, Market Area and Industry Position

9.7.2 Chinese Peptide Company Profile and Main Business

9.7.3 Chinese Peptide Peptide CDMO Pharmaceutical Models, Specifications and Application

9.7.4 Chinese Peptide Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.7.5 Chinese Peptide Recent Developments

9.8 Csbio

9.8.1 Csbio Company Information, Head Office, Market Area and Industry Position

9.8.2 Csbio Company Profile and Main Business

9.8.3 Csbio Peptide CDMO Pharmaceutical Models, Specifications and Application

9.8.4 Csbio Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.8.5 Csbio Recent Developments

9.9 Corden Pharma

9.9.1 Corden Pharma Company Information, Head Office, Market Area and Industry Position

9.9.2 Corden Pharma Company Profile and Main Business

9.9.3 Corden Pharma Peptide CDMO Pharmaceutical Models, Specifications and Application

9.9.4 Corden Pharma Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.9.5 Corden Pharma Recent Developments

9.10 Polypeptide

9.10.1 Polypeptide Company Information, Head Office, Market Area and Industry Position

9.10.2 Polypeptide Company Profile and Main Business

9.10.3 Polypeptide Peptide CDMO Pharmaceutical Models, Specifications and Application

9.10.4 Polypeptide Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.10.5 Polypeptide Recent Developments

9.11 Hybio Pharmaceutical

9.11.1 Hybio Pharmaceutical Company Information, Head Office, Market Area and Industry Position

9.11.2 Hybio Pharmaceutical Company Profile and Main Business

9.11.3 Hybio Pharmaceutical Peptide CDMO Pharmaceutical Models, Specifications and Application

9.11.4 Hybio Pharmaceutical Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.11.5 Hybio Pharmaceutical Recent Developments

9.12 Peptide Institute

9.12.1 Peptide Institute Company Information, Head Office, Market Area and Industry Position

9.12.2 Peptide Institute Company Profile and Main Business

9.12.3 Peptide Institute Peptide CDMO Pharmaceutical Models, Specifications and Application

9.12.4 Peptide Institute Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.12.5 Peptide Institute Recent Developments

9.13 Pepscan

9.13.1 Pepscan Company Information, Head Office, Market Area and Industry Position

9.13.2 Pepscan Company Profile and Main Business

9.13.3 Pepscan Peptide CDMO Pharmaceutical Models, Specifications and Application

9.13.4 Pepscan Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.13.5 Pepscan Recent Developments

9.14 Almac

9.14.1 Almac Company Information, Head Office, Market Area and Industry Position

9.14.2 Almac Company Profile and Main Business

9.14.3 Almac Peptide CDMO Pharmaceutical Models, Specifications and Application

9.14.4 Almac Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.14.5 Almac Recent Developments

9.15 Vivitide

9.15.1 Vivitide Company Information, Head Office, Market Area and Industry Position

9.15.2 Vivitide Company Profile and Main Business

9.15.3 Vivitide Peptide CDMO Pharmaceutical Models, Specifications and Application

9.15.4 Vivitide Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.15.5 Vivitide Recent Developments

9.16 Creosalus Inc

9.16.1 Creosalus Inc Company Information, Head Office, Market Area and Industry Position

9.16.2 Creosalus Inc Company Profile and Main Business

9.16.3 Creosalus Inc Peptide CDMO Pharmaceutical Models, Specifications and Application

9.16.4 Creosalus Inc Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.16.5 Creosalus Inc Recent Developments

9.17 Scinopharm

9.17.1 Scinopharm Company Information, Head Office, Market Area and Industry Position

9.17.2 Scinopharm Company Profile and Main Business

9.17.3 Scinopharm Peptide CDMO Pharmaceutical Models, Specifications and Application

9.17.4 Scinopharm Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.17.5 Scinopharm Recent Developments

9.18 Senn Chemicals

9.18.1 Senn Chemicals Company Information, Head Office, Market Area and Industry Position

9.18.2 Senn Chemicals Company Profile and Main Business

9.18.3 Senn Chemicals Peptide CDMO Pharmaceutical Models, Specifications and Application

9.18.4 Senn Chemicals Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.18.5 Senn Chemicals Recent Developments

9.19 Belyntic

9.19.1 Belyntic Company Information, Head Office, Market Area and Industry Position

9.19.2 Belyntic Company Profile and Main Business

9.19.3 Belyntic Peptide CDMO Pharmaceutical Models, Specifications and Application

9.19.4 Belyntic Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.19.5 Belyntic Recent Developments

9.20 Ferring Pharma

9.20.1 Ferring Pharma Company Information, Head Office, Market Area and Industry Position

9.20.2 Ferring Pharma Company Profile and Main Business

9.20.3 Ferring Pharma Peptide CDMO Pharmaceutical Models, Specifications and Application

9.20.4 Ferring Pharma Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.20.5 Ferring Pharma Recent Developments

9.21 Numaferm

9.21.1 Numaferm Company Information, Head Office, Market Area and Industry Position

9.21.2 Numaferm Company Profile and Main Business

9.21.3 Numaferm Peptide CDMO Pharmaceutical Models, Specifications and Application

9.21.4 Numaferm Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.21.5 Numaferm Recent Developments

9.22 Hybio Pharmaceutical

9.22.1 Hybio Pharmaceutical Company Information, Head Office, Market Area and Industry Position

9.22.2 Hybio Pharmaceutical Company Profile and Main Business

9.22.3 Hybio Pharmaceutical Peptide CDMO Pharmaceutical Models, Specifications and Application

9.22.4 Hybio Pharmaceutical Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.22.5 Hybio Pharmaceutical Recent Developments

9.23 Provepharm Life Solutions

9.23.1 Provepharm Life Solutions Company Information, Head Office, Market Area and Industry Position

9.23.2 Provepharm Life Solutions Company Profile and Main Business

9.23.3 Provepharm Life Solutions Peptide CDMO Pharmaceutical Models, Specifications and Application

9.23.4 Provepharm Life Solutions Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.23.5 Provepharm Life Solutions Recent Developments

9.24 Enzene Biosciences

9.24.1 Enzene Biosciences Company Information, Head Office, Market Area and Industry Position

9.24.2 Enzene Biosciences Company Profile and Main Business

9.24.3 Enzene Biosciences Peptide CDMO Pharmaceutical Models, Specifications and Application

9.24.4 Enzene Biosciences Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.24.5 Enzene Biosciences Recent Developments

9.25 Piramal Pharma

9.25.1 Piramal Pharma Company Information, Head Office, Market Area and Industry Position

9.25.2 Piramal Pharma Company Profile and Main Business

9.25.3 Piramal Pharma Peptide CDMO Pharmaceutical Models, Specifications and Application

9.25.4 Piramal Pharma Peptide CDMO Pharmaceutical Revenue and Gross Margin, 2019-2024

9.25.5 Piramal Pharma Recent Developments

10 Conclusion

11 Appendix

11.1 Research Methodology

11.2 Data Source

11.2.1 Secondary Sources

11.2.2 Primary Sources

11.3 Market Estimation Model

11.4 Disclaimer

Table 1. Peptide CDMO Pharmaceutical Consumption Value & CAGR: China VS Global, 2019-2030, US$ Million

Table 2. Peptide CDMO Pharmaceutical Market Restraints

Table 3. Peptide CDMO Pharmaceutical Market Trends

Table 4. Peptide CDMO Pharmaceutical Industry Policy

Table 5. Global Peptide CDMO Pharmaceutical Revenue by Company, 2019-2024, US$ million, Ranked Based on Revenue in 2022

Table 6. Global Peptide CDMO Pharmaceutical Revenue Share by Company, 2019-2024, Ranked by Data of 2022

Table 7. Global Peptide CDMO Pharmaceutical Manufacturers Market Concentration Ratio (CR3 and HHI)

Table 8. Global Peptide CDMO Pharmaceutical Mergers & Acquisitions, Expansion Plans

Table 9. Global Peptide CDMO Pharmaceutical Major Companies Product Type

Table 10. Head Office and Area Served of Key Players

Table 11. China Peptide CDMO Pharmaceutical Revenue by Company, 2019-2024, US$ million, Ranked Based on Revenue in 2022

Table 12. China Peptide CDMO Pharmaceutical Revenue Market Share by Company, 2019-2024

Table 13. Global Key Players of Peptide CDMO Pharmaceutical Upstream (Raw Materials)

Table 14. Global Peptide CDMO Pharmaceutical Typical Customers

Table 15. Peptide CDMO Pharmaceutical Typical Distributors

Table 16. By Type, Global Peptide CDMO Pharmaceutical Consumption Value & CAGR, 2019 VS 2024 VS 2030, US$ Million

Table 17. By Application, Global Peptide CDMO Pharmaceutical Consumption Value & CAGR, 2019 VS 2024 VS 2030, US$ Million

Table 18. By Region, Global Peptide CDMO Pharmaceutical Consumption Value, 2019 VS 2024 VS 2030, US$ Million

Table 19. By Region, Global Peptide CDMO Pharmaceutical Consumption Value, 2019-2030, US$ Million

Table 20. By Country, Global Peptide CDMO Pharmaceutical Consumption Value & CAGR, 2019 VS 2024 VS 2030, US$ Million

Table 21. By Country, Global Peptide CDMO Pharmaceutical Consumption Value, 2019-2030, US$ Million

Table 22. By Country, Global Peptide CDMO Pharmaceutical Consumption Value Market Share, 2019-2030

Table 23. Ambiopharm Company Information, Head Office, Market Area and Industry Position

Table 24. Ambiopharm Company Profile and Main Business

Table 25. Ambiopharm Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 26. Ambiopharm Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 27. Ambiopharm Recent Developments

Table 28. Auspep Company Information, Head Office, Market Area and Industry Position

Table 29. Auspep Company Profile and Main Business

Table 30. Auspep Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 31. Auspep Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 32. Auspep Recent Developments

Table 33. Bachem Company Information, Head Office, Market Area and Industry Position

Table 34. Bachem Company Profile and Main Business

Table 35. Bachem Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 36. Bachem Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 37. Bachem Recent Developments

Table 38. Bcn Peptide Company Information, Head Office, Market Area and Industry Position

Table 39. Bcn Peptide Company Profile and Main Business

Table 40. Bcn Peptide Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 41. Bcn Peptide Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 42. Bcn Peptide Recent Developments

Table 43. Cpc Scientific Company Information, Head Office, Market Area and Industry Position

Table 44. Cpc Scientific Company Profile and Main Business

Table 45. Cpc Scientific Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 46. Cpc Scientific Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 47. Cpc Scientific Recent Developments

Table 48. Creative Peptides Company Information, Head Office, Market Area and Industry Position

Table 49. Creative Peptides Company Profile and Main Business

Table 50. Creative Peptides Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 51. Creative Peptides Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 52. Creative Peptides Recent Developments

Table 53. Chinese Peptide Company Information, Head Office, Market Area and Industry Position

Table 54. Chinese Peptide Company Profile and Main Business

Table 55. Chinese Peptide Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 56. Chinese Peptide Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 57. Chinese Peptide Recent Developments

Table 58. Csbio Company Information, Head Office, Market Area and Industry Position

Table 59. Csbio Company Profile and Main Business

Table 60. Csbio Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 61. Csbio Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 62. Csbio Recent Developments

Table 63. Corden Pharma Company Information, Head Office, Market Area and Industry Position

Table 64. Corden Pharma Company Profile and Main Business

Table 65. Corden Pharma Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 66. Corden Pharma Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 67. Corden Pharma Recent Developments

Table 68. Polypeptide Company Information, Head Office, Market Area and Industry Position

Table 69. Polypeptide Company Profile and Main Business

Table 70. Polypeptide Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 71. Polypeptide Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 72. Polypeptide Recent Developments

Table 73. Hybio Pharmaceutical Company Information, Head Office, Market Area and Industry Position

Table 74. Hybio Pharmaceutical Company Profile and Main Business

Table 75. Hybio Pharmaceutical Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 76. Hybio Pharmaceutical Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 77. Hybio Pharmaceutical Recent Developments

Table 78. Peptide Institute Company Information, Head Office, Market Area and Industry Position

Table 79. Peptide Institute Company Profile and Main Business

Table 80. Peptide Institute Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 81. Peptide Institute Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 82. Peptide Institute Recent Developments

Table 83. Pepscan Company Information, Head Office, Market Area and Industry Position

Table 84. Pepscan Company Profile and Main Business

Table 85. Pepscan Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 86. Pepscan Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 87. Pepscan Recent Developments

Table 88. Almac Company Information, Head Office, Market Area and Industry Position

Table 89. Almac Company Profile and Main Business

Table 90. Almac Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 91. Almac Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 92. Almac Recent Developments

Table 93. Vivitide Company Information, Head Office, Market Area and Industry Position

Table 94. Vivitide Company Profile and Main Business

Table 95. Vivitide Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 96. Vivitide Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 97. Vivitide Recent Developments

Table 98. Creosalus Inc Company Information, Head Office, Market Area and Industry Position

Table 99. Creosalus Inc Company Profile and Main Business

Table 100. Creosalus Inc Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 101. Creosalus Inc Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 102. Creosalus Inc Recent Developments

Table 103. Scinopharm Company Information, Head Office, Market Area and Industry Position

Table 104. Scinopharm Company Profile and Main Business

Table 105. Scinopharm Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 106. Scinopharm Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 107. Scinopharm Recent Developments

Table 108. Senn Chemicals Company Information, Head Office, Market Area and Industry Position

Table 109. Senn Chemicals Company Profile and Main Business

Table 110. Senn Chemicals Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 111. Senn Chemicals Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 112. Senn Chemicals Recent Developments

Table 113. Belyntic Company Information, Head Office, Market Area and Industry Position

Table 114. Belyntic Company Profile and Main Business

Table 115. Belyntic Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 116. Belyntic Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 117. Belyntic Recent Developments

Table 118. Ferring Pharma Company Information, Head Office, Market Area and Industry Position

Table 119. Ferring Pharma Company Profile and Main Business

Table 120. Ferring Pharma Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 121. Ferring Pharma Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 122. Ferring Pharma Recent Developments

Table 123. Numaferm Peptide CDMO Pharmaceutical Company Information, Head Office, Market Area and Industry Position

Table 124. Numaferm Company Profile and Main Business

Table 125. Numaferm Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 126. Numaferm Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 127. Numaferm Recent Developments

Table 128. Hybio Pharmaceutical Company Information, Head Office, Market Area and Industry Position

Table 129. Hybio Pharmaceutical Company Profile and Main Business

Table 130. Hybio Pharmaceutical Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 131. Hybio Pharmaceutical Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 132. Hybio Pharmaceutical Recent Developments

Table 133. Provepharm Life Solutions Company Information, Head Office, Market Area and Industry Position

Table 134. Provepharm Life Solutions Company Profile and Main Business

Table 135. Provepharm Life Solutions Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 136. Provepharm Life Solutions Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 137. Provepharm Life Solutions Recent Developments

Table 138. Enzene Biosciences Company Information, Head Office, Market Area and Industry Position

Table 139. Enzene Biosciences Company Profile and Main Business

Table 140. Enzene Biosciences Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 141. Enzene Biosciences Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 142. Enzene Biosciences Recent Developments

Table 143. Piramal Pharma Company Information, Head Office, Market Area and Industry Position

Table 144. Piramal Pharma Company Profile and Main Business

Table 145. Piramal Pharma Peptide CDMO Pharmaceutical Models, Specifications, and Application

Table 146. Piramal Pharma Peptide CDMO Pharmaceutical Revenue and Gross Margin, US$ Million, 2019-2024

Table 147. Piramal Pharma Recent Developments

List of Figures

Figure 1. Peptide CDMO Pharmaceutical Picture

Figure 2. Global Peptide CDMO Pharmaceutical Consumption Value, (US$ million) & (2019-2030)

Figure 3. China Peptide CDMO Pharmaceutical Consumption Value, (US$ million) & (2019-2030)

Figure 4. By Consumption Value, China Peptide CDMO Pharmaceutical Market Share of Global, 2019-2030

Figure 5. Global Peptide CDMO Pharmaceutical Market Share by Company, (Tier 1, Tier 2, and Tier 3), 2022

Figure 6. China Peptide CDMO Pharmaceutical Key Participants, Market Share, 2022

Figure 7. Peptide CDMO Pharmaceutical Industry Chain

Figure 8. Peptide CDMO Pharmaceutical Procurement Model

Figure 9. Peptide CDMO Pharmaceutical Sales Model

Figure 10. Peptide CDMO Pharmaceutical Sales Channels, Direct Sales, and Distribution

Figure 11. Liquid-phase Peptide Synthesis（LPPS）

Figure 12. Solid-phase Peptide Synthesis（SPPS）

Figure 13. Mixed Phase

Figure 14. By Type, Global Peptide CDMO Pharmaceutical Consumption Value, 2019-2030, US$ Million

Figure 15. By Type, Global Peptide CDMO Pharmaceutical Consumption Value Market Share, 2019-2030

Figure 16. Peptide Supplements

Figure 17. Peptide Vaccines

Figure 18. Others

Figure 19. By Application, Global Peptide CDMO Pharmaceutical Consumption Value, 2019-2030, US$ Million

Figure 20. By Application, Global Peptide CDMO Pharmaceutical Consumption Value Market Share, 2019-2030

Figure 21. By Region, Global Peptide CDMO Pharmaceutical Consumption Value Market Share, 2019-2030

Figure 22. North America Peptide CDMO Pharmaceutical Consumption Value & Forecasts, 2019-2030, US$ Million

Figure 23. By Country, North America Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022

Figure 24. Europe Peptide CDMO Pharmaceutical Consumption Value & Forecasts, 2019-2030, US$ Million

Figure 25. By Country, Europe Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022

Figure 26. Asia Pacific Peptide CDMO Pharmaceutical Consumption Value & Forecasts, 2019-2030, US$ Million

Figure 27. By Country/Region, Asia Pacific Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022

Figure 28. South America Peptide CDMO Pharmaceutical Consumption Value & Forecasts, 2019-2030, US$ Million

Figure 29. By Country, South America Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022

Figure 30. Middle East & Africa Peptide CDMO Pharmaceutical Consumption Value & Forecasts, 2019-2030, US$ Million

Figure 31. U.S. Peptide CDMO Pharmaceutical Consumption Value, 2019-2030, US$ Million

Figure 32. By Type, U.S. Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

Figure 33. By Application, U.S. Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

Figure 34. Europe Peptide CDMO Pharmaceutical Consumption Value, 2019-2030, US$ Million

Figure 35. By Type, Europe Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

Figure 36. By Application, Europe Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

Figure 37. China Peptide CDMO Pharmaceutical Consumption Value, 2019-2030, US$ Million

Figure 38. By Type, China Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

Figure 39. By Application, China Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

Figure 40. Japan Peptide CDMO Pharmaceutical Consumption Value, 2019-2030, US$ Million

Figure 41. By Type, Japan Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

Figure 42. By Application, Japan Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

Figure 43. South Korea Peptide CDMO Pharmaceutical Consumption Value, 2019-2030, US$ Million

Figure 44. By Type, South Korea Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

Figure 45. By Application, South Korea Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

Figure 46. Southeast Asia Peptide CDMO Pharmaceutical Consumption Value, 2019-2030, US$ Million

Figure 47. By Type, Southeast Asia Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

Figure 48. By Application, Southeast Asia Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

Figure 49. India Peptide CDMO Pharmaceutical Consumption Value, 2019-2030, US$ Million

Figure 50. By Type, India Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

Figure 51. By Application, India Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

Figure 52. Middle East & Africa Peptide CDMO Pharmaceutical Consumption Value, 2019-2030, US$ Million

Figure 53. By Type, Middle East & Africa Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

Figure 54. By Application, Middle East & Africa Peptide CDMO Pharmaceutical Consumption Value Market Share, 2022 VS 2029

Figure 55. Research Methodology

Figure 56. Breakdown of Primary Interviews

Figure 57. Bottom-up and Top-down Approaches

Figure 58. Top-down Approaches

Methodology/Research Approach

This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.

Research Programs/Design

Historical Data (2015-2019)	Industry Trends Competitive Landscape By Company Expansion Mergers and Acquisitions Market Segment by Type by Application By Regions/ Geography	Value Status and Outlook Value for Major Players Market Share Growth Rate Present Situation Analysis Value Market Share Growth Rate Present Situation Analysis
Influencing Factors	Market Environment Government Policy Technological Changes Market Risks	Market Drivers Growing Demand of Downstream Reduction in Cost
Market Forecast (2021-2026)	Overall Size by Type by Application By Regions/Geography	Key Data (Value) Market Share Growth Rate CAGR (2021-2026)

Market Size Estimation

Top-down and bottom-up approaches are used to validate the global Voluntary Carbon Offset market size market and estimate the market size for Company, regions segments, product segments and Application (end users).

The market estimations in this report are based on the marketed sale price of Voluntary Carbon Offset (excluding any discounts provided by the player, distributor, wholesaler or traders). The percentage splits, market share, and breakdowns of the product segments are derived on the basis of weights assigned to each of the segments on the basis of their utilization rate and average sale price. The regional splits of the overall Voluntary Carbon Offset market and its sub-segments are based on the percentage adoption or utilization of the given product in the respective region or country.

Major Company in the market is identified through secondary research and their market revenues determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top Company; whereas, primary research included extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs and marketing executives. The percentage splits, market share, Growth Rate and breakdowns of the product markets are determined through using secondary sources and verified through the primary sources.

All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Market Intellix and presented in this report

The following figure shows an illustrative representation of the overall market size estimation process used for this study.

Market Breakdown and Data Triangulation

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.

Data Source

Secondary Sources

Secondary sources include such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, etc. This research study involves the usage of widespread secondary sources, directories, databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), and TRADING ECONOMICS, and News Network, statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and Hospitals study of the Voluntary Carbon Offset market. It was also used to obtain important information about the top companies, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.

Market Size	Segmental value Geographic Penetration Product Adoption Rate for Different market	Journals, Websites, and Press Releases Annual Reports and SEC Filings Company Websites and Press Releases Public and Paid Databases Market Intellix Data Repository
Market Position of Top Company	Product Financials Geographic value Mix Total Company value Business/Segmental value Mix
Qualitative Analysis	Influence Factors Market Potential Market Risks and Opportunities Industry Trends Geographical Features Government Policies	Company Websites and Press Releases Public and Paid Databases Annual Reports Industry Associations Market Intellix Data Repository

Primary Sources

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product Company (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end use (product buyers), and related key executives from various key companies and organizations operating in the global market.

Primary research was conducted to identify segmentation Type, product price range, product Application, key Company, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.

Key Executives Interviewed

Key Data Information from Primary Sources

Primary Sources	Parameters	Key Data
Market Segments(by Application, by Type)	Value by Type Status and Forecast Value by Application Value by Regions, Status and Forecast (2021-2026)	Value Market Share by Type Value Growth Rate by Type Value by Application Percentage and Growth Rate by Application Value Growth Rate and Market Share by Regions Market Size Status and Forecast (2021-2026)
Total Market	Overall Size, Status and Forecast	Market Size Status and Forecast (2021-2026)